Combination of Tests Enhances Urinary Tract Infection Localization
By LabMedica International staff writers Posted on 14 Dec 2016 |

Image: The Mini VIDAS automatic quantitative fluorescence immunoassay analyzer (Photo courtesy of BioMérieux).
Conventional serum markers for diagnosing urinary tract infection include total white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and interleukin (IL)-6.
Urinary tract infections (UTIs) commonly occur in young febrile children and they trigger a wide range of bacterial infections. The combination of urinary beta 2 microglobulin (urinary β2-MG) and procalcitonin (PCT) diagnosis could enhance the localization diagnostic precision of pediatric UTI compared with a single diagnosis.
Scientists at the Wuhan Women and Children's Health Care Center (Hubei, China) enrolled 85 participants, including 35 children who were diagnosed as upper urinary tract infection (UUTI) with the symptom of fever and 50 children who had lower urinary tract infection (LUTI) from August 2014 to September 2015. Levels of PCT and urinary β2-MG in both UUTI and LUTI patients were measured and compared.
Blood and urine samples were collected and stored. Enzyme-linked fluorescent analysis was carried out, in which the relevant kits were purchased from BioMérieux (Lyons, France). Quantitative measurement was conducted using a Mini VIDAS automatic quantitative fluorescence immunoassay analyzer, also from BioMérieux. The results were considered positive when the PCT concentration was higher than 0.5 ng/mL. Urinary β2-MG levels were detected using a DPC1000 automatic chemiluminescence meter (DPC Industries, Omaha, NE, USA).
The investigators found that the mean level of PCT in the UUTI group was 1.37 ± 0.67 ng/mL, whereas that in the LUTI group was 0.53 ± 0.23 ng/mL. The mean levels of urinary β2-MG in the UUTI and LUTI groups were 1.08 ± 0.73 and 0.39 ± 0.21 μg/mL, respectively. The mean levels of serum PCT and urinary β2-MG in the UUTI group were significantly higher than those in the LUTI group, respectively. The area under the curve (AUC) of urinary β2-MG ROC (sensitivity of 71.4%, specificity of 90.0%) was significantly smaller than that of PCT ROC (sensitivity of 77.1%, specificity of 96.0%) in the single diagnosis. Although in the combined diagnosis, the sensitivity and specificity increased to 88.6% and 98%, respectively.
The authors concluded the combination of urinary β2-MG and serum PCT could increase the localization diagnosis accuracy, specificity, and sensitivity of pediatric UTI. Both PCT and β2-MG could be used to localize the UTI and introducing urinary β2-MG into PCT diagnosis could increase the sensitivity and specificity of UTI lesion diagnosis in clinical practice. The study was first published online on November 1, 2016, in the Journal of Clinical Laboratory Analysis.
Related Links:
Wuhan Women and Children's Health Care Center
BioMérieux
DPC Industries
Urinary tract infections (UTIs) commonly occur in young febrile children and they trigger a wide range of bacterial infections. The combination of urinary beta 2 microglobulin (urinary β2-MG) and procalcitonin (PCT) diagnosis could enhance the localization diagnostic precision of pediatric UTI compared with a single diagnosis.
Scientists at the Wuhan Women and Children's Health Care Center (Hubei, China) enrolled 85 participants, including 35 children who were diagnosed as upper urinary tract infection (UUTI) with the symptom of fever and 50 children who had lower urinary tract infection (LUTI) from August 2014 to September 2015. Levels of PCT and urinary β2-MG in both UUTI and LUTI patients were measured and compared.
Blood and urine samples were collected and stored. Enzyme-linked fluorescent analysis was carried out, in which the relevant kits were purchased from BioMérieux (Lyons, France). Quantitative measurement was conducted using a Mini VIDAS automatic quantitative fluorescence immunoassay analyzer, also from BioMérieux. The results were considered positive when the PCT concentration was higher than 0.5 ng/mL. Urinary β2-MG levels were detected using a DPC1000 automatic chemiluminescence meter (DPC Industries, Omaha, NE, USA).
The investigators found that the mean level of PCT in the UUTI group was 1.37 ± 0.67 ng/mL, whereas that in the LUTI group was 0.53 ± 0.23 ng/mL. The mean levels of urinary β2-MG in the UUTI and LUTI groups were 1.08 ± 0.73 and 0.39 ± 0.21 μg/mL, respectively. The mean levels of serum PCT and urinary β2-MG in the UUTI group were significantly higher than those in the LUTI group, respectively. The area under the curve (AUC) of urinary β2-MG ROC (sensitivity of 71.4%, specificity of 90.0%) was significantly smaller than that of PCT ROC (sensitivity of 77.1%, specificity of 96.0%) in the single diagnosis. Although in the combined diagnosis, the sensitivity and specificity increased to 88.6% and 98%, respectively.
The authors concluded the combination of urinary β2-MG and serum PCT could increase the localization diagnosis accuracy, specificity, and sensitivity of pediatric UTI. Both PCT and β2-MG could be used to localize the UTI and introducing urinary β2-MG into PCT diagnosis could increase the sensitivity and specificity of UTI lesion diagnosis in clinical practice. The study was first published online on November 1, 2016, in the Journal of Clinical Laboratory Analysis.
Related Links:
Wuhan Women and Children's Health Care Center
BioMérieux
DPC Industries
Latest Clinical Chem. News
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
Channels
Molecular Diagnostics
view channel
Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD
Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more